A recent imaging study assessing tumor uptake of a radiolabeled anti-VEGF antibody, such as the monoclonal antibody bevacizumab in glioma, showed unsatisfactory results with significant inter- and intra-patient heterogeneity [13]. Here, VEGFA is linked to central nervous system cancer.